The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank

Dale, J. et al. (2016) The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. BMC Musculoskeletal Disorders, 17, 461. (doi: 10.1186/s12891-016-1318-y) (PMID:27829394) (PMCID:PMC5103386)

131655.pdf - Published Version
Available under License Creative Commons Attribution.



Background: The Scottish Early Rheumatoid Arthritis (SERA) study is an inception cohort of rheumatoid (RA) and undifferentiated arthritis (UA) patients that aims to provide a contemporary description of phenotype and outcome and facilitate discovery of phenotypic and prognostic biomarkers Methods: Demographic and clinical outcome data are collected from newly diagnosed RA/UA patients every 6 months from around Scotland. Health service utilization data is acquired from Information Services Division, NHS National Services Scotland. Plain radiographs of hands and feet are collected at baseline and 12 months. Additional samples of whole blood, plasma, serum and filtered urine are collected at baseline, 6 and 12 months Results: Results are available for 1073 patients; at baseline, 76 % were classified as RA and 24 % as UA. Median time from onset to first review was 163 days (IQR97-323). Methotrexate was first-line DMARD for 75 % patients. Disease activity, functional ability and health-related quality of life improved significantly between baseline and 24 months, however the proportion in any employment fell (51 to 38 %, p = 0.0005). 24 % patients reported symptoms of anxiety and/or depression at baseline. 35/391 (9 %) patients exhibited rapid radiographic progression after 12 months. The SERA Biobank has accrued 60,612 samples Conclusions: In routine care, newly diagnosed RA/UA patients experience significant improvements in disease activity, functional ability and health-related quality of life but have high rates of psychiatric symptoms and declining employment rates. The co-existence of a multi-domain description of phenotype and a comprehensive biobank will facilitate multi-platform translational research to identify predictive markers of phenotype and prognosis.

Item Type:Articles
Additional Information:The SERA study was jointly supported by the Chief Scientist’s Office Scotland (ETM-40) and Pfizer Ltd.
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain and Saunders, Dr Sarah and Munro, Dr Robin and Paterson, Miss Caron and Dale, Dr James and Reid, Professor David and Siebert, Professor Stefan and Basu, Professor Neil and Porter, Dr Duncan and Wilson, Dr Hilary
Authors: Dale, J., Paterson, C., Tierney, A., Ralston, S. H., Reid, D. M., Basu, N., Harvie, J., McKay, N. D., Saunders, S., Wilson, H., Munro, R., Richmond, R., Baxter, D., McMahon, M., McLaren, J., Kumar, V., Siebert, S., McInnes, I., and Porter, D.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:BMC Musculoskeletal Disorders
Publisher:BioMed Central
ISSN (Online):1471-2474
Copyright Holders:Copyright © 2016 The Authors
First Published:First published in BMC Musculoskeletal Disorders 17: 461
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record